Datapoint: AbbVie’s Rinvoq Chalks Up Atopic Dermatitis Win

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 24

The FDA on Jan. 14 approved AbbVie’s Rinvoq for the treatment of moderate to severe atopic dermatitis in adults and children 12 and older who have not responded to previous treatments. The JAK inhibitor was approved for daily use in both its 15mg and 30mg strengths, which could give it a competitive edge. For the treatment of rheumatoid arthritis, Rinvoq currently holds covered or better status for 96% of all insured lives under the pharmacy benefit. 37% of covered lives have preferred access to Rinvoq.

SOURCE: MMIT Analytics, as of 1/19/22

0
0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 6

Datapoint: Friday Health Plans to Shut Down

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 5

Datapoint: Kaiser Commits Up to $10M in Funding to Colorado System

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 1

Datapoint: FDA Approves Lexicon’s Heart Failure Drug

Read More

The Latest

enhance-patient-assistance-programs

Meet Our Reporters

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today